"10.1371_journal.pone.0064733","plos one","2013-08-26T00:00:00Z","Sylvie Bastuji-Garin; Emilie Sbidian; Caroline Gaudy-Marqueste; Emilie Ferrat; Jean-Claude Roujeau; Marie-Aleth Richard; Florence Canoui-Poitrine; on behalf of the European Dermatology Network (EDEN)","Université Paris Est Créteil (UPEC), LIC EA4393 (Laboratoire dInvestigation Clinique), Créteil, France; AP-HP, Hôpital Henri-Mondor, Department of Clinical Research and Public Health, Créteil, France; AP-HP, Hôpital Henri-Mondor, Unité de Recherche Clinique (URC), Créteil, France; AP-HP, Hôpital Henri-Mondor, Department of Dermatology, Créteil, France; AP-HM, Timone University, Department of Dermatology, Marseille, France; Université Paris Est Créteil (UPEC), Faculté de Medecine, Department of General Practice, Créteil, France","¶ Membership of the EDEN Group is provided in the Acknowledgments.","The authors declare no support from any organisation for the submitted work. Prof. Bastuji-Garin received speaker fees from Astra-Zeneca France from 2007 to 2011. Prof. Roujeau reported occasional consulting for AB Science; being a former member of the boards of Vertex, Servier, Janssen, Boehringer-Ingelheim, and OM-Pharma; and receiving speaker fees from Menarini in 2011. Prof. Richard reported consulting activities for Pfizer, Leo Pharma, Janssen, Galderma, Abbott, and Novartis; and receiving fees for service on speakers bureaus from Pfizer, Leo Pharma, Janssen, Galderma, Abbott, Pierre Fabre, Merck, and BMS. Dr Sbidian reported receiving fees from Abbott in 2010. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","08","Sylvie Bastuji-Garin","SBG",8,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
